Medical News

RSS

Protect Pharma completes sale of two patents and patents-applications to Grunenthal

Protect Pharmaceutical Corporation announced that it has completed the sale of two patents and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes innovative pain drugs that address the large and underserved pain market.

9 Feb 2011

Clinical Data reports $2.0 million revenue for third quarter 2011

Clinical Data, Inc. today announced operational and financial results for the third fiscal quarter ended December 31, 2010. The Company received approval from the U.S. Food and Drug Administration (FDA) of Viibryd™ for the treatment of adults with major depressive disorder (MDD) on January 21, 2011.

9 Feb 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.

9 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a second clinical trial site at the Alabama Vaccine Research Clinic (AVRC) of the University of Alabama at Birmingham (UAB) to expand the company's HIV therapeutic vaccine trial.

9 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

First Edition: February 9, 2011

Today's headlines include news about GOP plans to defund the health law and stepped up Capitol Hill activity surrounding the abortion issue.

9 Feb 2011

Virtues of Patient Protection and Affordable Care Act a 'mixed bag' for older Americans

Although the effects of the controversial health care reform act will be somewhat muted for many older Americans, it will inevitably have enough of an impact that seniors will discover that there is plenty to like and dislike about the law, a University of Illinois expert on elder law cautions in published research.

9 Feb 2011

DiaTech, Walter Reed collaborate to determine the best chemotherapy for cancer

DiaTech Oncology announced today they have engaged in a pilot with Walter Reed Army Medical Center to determine the best Chemotherapy for Cancer patients. Medical and GYN Oncologists and from Walter Reed have been working with DiaTech Oncology (Nashville, TN) using the MiCK assay for apoptosis in order to give physicians a tool that can predict the best chemotherapy pathway in treating cancer patients.

9 Feb 2011

BBSRC, EMBL-EBI applaud funding allocation for European Life-science Infrastructure for Biological Information

The Biotechnology and Biological Sciences Research Council (BBSRC) and the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI) welcome news that funding has been earmarked from the UK's Large Facilities Capital Fund for ELIXIR - the European Life-science Infrastructure for Biological Information - as announced today (09 February 2011).

9 Feb 2011

A.P. Pharma provides update on response to APF530 Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today provided an update on its progress toward responding to the Complete Response Letter for APF530 that the Company received from the U.S. Food and Drug Administration (FDA) in March 2010.

9 Feb 2011

Single molecule imaging movies of living cell membranes clarify enigma surrounding receptor molecule behaviors

Unprecedented single molecule imaging movies of living cell membranes, taken by a research team based at Kyoto University and the University of New Mexico, have clarified a decades-old enigma surrounding receptor molecule behaviors. The results, appearing in the latest issue of the Journal of Cell Biology, promise to open the door to new possibilities for drug development.

9 Feb 2011

Iworx introduces 2011 Product Catalog of physiology teaching and advanced research solutions

iWorx, a developer of advanced physiology research and teaching tools, has introduced its 2011 Product Catalog of physiology teaching and advanced research solutions.

9 Feb 2011

Rapid detection of transiently folded single-molecule structures from 'intrinsically disordered proteins'

A team of scientists from The Scripps Research Institute and the University of California, San Diego (UCSD) have developed a novel technique to observe previously unknown details of how folded structures are formed from an intrinsically disordered protein. The insights could help scientists to better understand the mechanism of plaque formation in neurodegenerative disorders such as Parkinson's and Alzheimer's diseases.

9 Feb 2011

MedRisk creates Risk Information and Business Intelligence unit

MedRisk, Inc., the workers' compensation industry leader in specialty managed care services, has announced the creation of its Risk Information and Business Intelligence (RIBI) unit. RIBI's first initiative is to roll out a new reporting platform featuring state-of-the-art graphics and outcomes analytics.

9 Feb 2011

Tibet Pharmaceuticals launches new corporate website

Tibet Pharmaceuticals, Inc., an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announces the launch of a new corporate website.

9 Feb 2011

International AIDS Society urges donors and governments to continue funding

Following the publication of several media reports which seriously distort the extent of fraud discovered in grants financed by the Global Fund to Fight AIDS, TB and Malaria, the International AIDS Society (IAS) urges all donors and governments to continue their funding.

9 Feb 2011

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Eviagenics, a French biotech company, is pleased to announce the closing of a series A financing round to scale up its technical and commercial development. At this occasion the FCPR Emertec 4 managed by Emertec Management, CEA Investissement, and Genopole Premier Jour managed by CapDecisif Management provide a total contribution of EUR 1.3 million.

9 Feb 2011

Prestige Brands third quarter revenues increase 22.7% to $90.6 million

Prestige Brands Holdings, Inc. today announced results for the third quarter and nine months of fiscal year 2011, which ended on December 31, 2010. Following the close of the quarter, the Company completed the previously announced acquisition of the Dramamine® Brand in the U.S. from McNeil-PPC, Inc.

9 Feb 2011

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

QLT Inc. today announced results from a Phase II proof-of-concept clinical trial for the olopatadine punctal plug delivery system (O‑PPDS).

9 Feb 2011

Medical News

Protect Pharma completes sale of two patents and patents-applications to Grunenthal

Clinical Data reports $2.0 million revenue for third quarter 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

Repligen third quarter total revenue increases 26% to $7,068,000

GeoVax opens second HIV clinical trial site at Alabama Vaccine Research Clinic

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

First Edition: February 9, 2011

Virtues of Patient Protection and Affordable Care Act a 'mixed bag' for older Americans

DiaTech, Walter Reed collaborate to determine the best chemotherapy for cancer

BBSRC, EMBL-EBI applaud funding allocation for European Life-science Infrastructure for Biological Information

A.P. Pharma provides update on response to APF530 Complete Response Letter

Single molecule imaging movies of living cell membranes clarify enigma surrounding receptor molecule behaviors

Iworx introduces 2011 Product Catalog of physiology teaching and advanced research solutions

Rapid detection of transiently folded single-molecule structures from 'intrinsically disordered proteins'

MedRisk creates Risk Information and Business Intelligence unit

Tibet Pharmaceuticals launches new corporate website

International AIDS Society urges donors and governments to continue funding

Eviagenics closes financing round for EUR 1.3 million to commercialize its technology platform

Prestige Brands third quarter revenues increase 22.7% to $90.6 million

QLT's Phase II olopatadine punctal plug delivery system trial demonstrates safety in allergic conjunctivitis patients

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News